Introduction {#Sec1}
============

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the progressive decline in memory, language, cognition and motor functions. The neuropathological hallmarks of AD are the accumulation of extracellular amyloid plaques containing the amyloid beta peptide (Aβ) and intraneuronal neurofibrillary tangles containing hyperphosphorylated microtubule-associated protein tau. Although the initiating molecular event(s) in AD are not known, oxidative stress produced by the generation of reactive oxygen species (ROS) appears to be a fundamental process contributing to the neuropathophysiology \[[@CR10]\]. Whether oxidative stress has a role in the cause or affect in AD has been debated for many years, but recent research has suggested that it occurs prior to the onset of symptoms \[[@CR35]\]. The histopathological evidence for oxidative stress in AD includes lipid, protein and DNA oxidation. There is evidence to suggest that oxidative stress is generated peripherally \[[@CR26]\] with the brain being particularly susceptible, but there is also a body of evidence to suggest that amyloid β peptide (Aβ42) may be linked to lipid peroxidation \[[@CR5], [@CR6]\], which may then be linked to the phosphorylation of tau \[[@CR24]\]. Two reactive products of Aβ42-induced lipid peroxidation are the production of four hydroxynonenal and acrolein \[[@CR5]\], which have been shown to disrupt membrane asymmetry \[[@CR7]\] and may be involved in the conformational changes to tau, promoting the formation of neurofibrillary tangles \[[@CR24]\].

Oxidative damage occurs as part of the aging process, but it occurs at a much greater rate in most neurodegenerative diseases \[[@CR3]\]. The hallmark of protein oxidation is the generation of protein carbonyls, which are markedly elevated in AD \[[@CR3], [@CR16]\]. There is overwhelming evidence to implicate oxidative stress in the pathogenesis of AD, and this is most likely an early event in the disease process. Less is known however of how the brain responds to oxidative insults. There are a number of cellular antioxidant defenses whose primary role is to convert the ROS into unreactive compounds. These defense mechanisms include superoxide dismutase, which works together with selenium-dependent glutathione peroxidase, catalase and more recently the peroxiredoxin family. These enzymes transform the superoxide radical to hydrogen peroxide~,~ which in turn is converted to water. The distribution and changes in expression of the antioxidant enzymes have not been well studied as the other aspects of the disease process.

Cellular selenium-dependant glutathione peroxidase (GPx-1) has long been regarded as the major cellular antioxidant enzyme, but there are conflicting reports regarding the changes in activities of this enzyme in AD. Early reports suggest that there is no change in GPx-1 activities in AD brains \[[@CR15], [@CR20]\], while other researchers suggest that there is a decrease in GPx-1 activity \[[@CR8], [@CR27], [@CR32]\]. There are no reports indicating compensatory increase in GPx-1 activity; however, cell models overexpressing GPx-1 are more resistant to Aβ-mediated toxicity, suggesting that increased levels of GPx-1 is protective \[[@CR2]\].

There is considerable evidence to implicate Aβ toxicity and the generation of ROS and in particular hydrogen peroxide as key steps in contributing to the neurotoxicity in AD. We have previously reported that peroxiredoxin 6, also termed 1 Cys-peroxiredoxin or nonselenium glutathione peroxidase, is upregulated in Parkinson's disease (PD) \[[@CR30]\]. This enzyme has no amino acid homology to any known sequence of the glutathione peroxidase enzymes and has both antioxidant and phospholipase A2 activity and can reduce hydroxyperoxides \[[@CR9]\]. Given that the brain is particularly vulnerable to oxidative damage due to its high energy and oxygen requirements, high levels of transition metals and peroxidizable fatty acids suggests that peroxiredoxin 6 could play a key antioxidant role in neuroprotection.

There are six members of the peroxiredoxin family at this stage with peroxiredoxins 1--5 being the 2-Cys members while peroxiredoxin 6 is the sole 1-Cys member \[[@CR36]\]. This enzyme is bifunctional with 80% of its function as a peroxidase and the remainder as a phospholipase A2. Peroxiredoxin 6 has not specifically been examined in brain tissue of AD patients, and the aims of this study are to examine the molecular forms, cellular distribution and association with AD pathology. This study focused on the cingulate, amygdala, hippocampus and cortical regions in six AD and six control brains.

Materials and methods {#Sec2}
=====================

Antibodies {#Sec3}
----------

### Primary antibodies {#Sec4}

Peroxiredoxin 6 (rabbit) was obtained from Antibody Technology Australia Pty, Ltd, Adelaide, Australia. Tau (mouse) was obtained from Novacastra Laboratories Ltd, Newcastle, UK. Tau (goat) was obtained from Santa Cruz Biotechnology Inc., California, USA. Amyloid beta (mouse) was obtained from Novacastra Laboratories Ltd, Newcastle, UK. Glial fibrillary acidic protein (GFAP) (mouse) was obtained from Novacastra Laboratories Ltd, Newcastle, UK. Human neuronal protein HuC/HuD (mouse) was obtained from Molecular Probes Inc., Eugene, USA. Human HLA (MHC2) (mouse) was obtained from Dakocytomation, Denmark A/S. Myelin basic protein (MBP) (mouse) was obtained from Novacastra Laboratories Ltd, Newcastle, UK.

### Secondary antibodies {#Sec5}

Donkey anti sheep Cy3 was obtained from Jackson Immunoresearch, West Grove, USA. Donkey antirabbit Cy3 and Cy5 were obtained from Jackson Immunoresearch, West Grove, USA. Goat antimouse Alexa 488 was obtained from Molecular Probes Inc., Eugene, USA. Goat antirabbit alkaline phosphatase was obtained from Sigma Chemical Company, St Louis, USA.

Brain tissue {#Sec6}
------------

The brain tissue was obtained from the National Health and Medical Research Council South Australian Brain Bank. Brains were removed at autopsy from clinically diagnosed AD cases and confirmed pathologically postmortem. The control cases were obtained from people who died of unrelated causes without diagnosed neurological pathology that was confirmed postmortem. The brains were bisected and one half snap-frozen at −80°C and the other immersion fixed in buffered formaldehyde. Tissue blocks were processed and embedded in paraffin and 8 μm sections were cut and mounted onto gelatin-coated slides. Table [1](#Tab1){ref-type="table"} provides a list of the brain regions examined and the case details. Table 1List of cases used in cell countingCase numberSexAge (years)DiagnosisRegionPMI (h)Braak stageNIA ReaganAD1M65ADC, A, H, MC35/6HighAD2F84ADC, A, H, MC165/6HighAD3M63ADC, A, H, MC335/6HighAD4M59ADC, A, H, MC205/6HighAD5F81ADC, A, H, MC195/6HighAD6F69ADC, A, H, MC385/6HighC1F79ADLC, A, H, MC4LowC2M69UnkC, A, H, MC48LowC3F61CFC, A, H, MC8LowC4F84SSC, A, H, MC15LowC5F86DMC, A, H, MC17LowC6F86HVDC, A, H, MC6Low*PMI* postmortem index, *AD* Alzheimer's disease, *NIA Reagan* high or low likely-hood of AD*, M* male, *F* female, *C* cingulate, *A* amygdala, *H* hippocampus, *MC* midfrontal cortex, *C* control, *ADL* adeno lung carcinoma, *Unk* unknown, *CF* cardiac failure, *SS* septic shock, *DM* disseminated malignancy, *HVD* hypertensive vascular disease

Brain homogenate {#Sec7}
----------------

Frozen tissue from midfrontal cortex of three AD brains and three control cases were homogenized in 50 mM Tris, 5 mM EDTA, 0.1% sodium azide, 1 μl/ml pepstatin and leupeptin and 0.3 mM of phenylmethylsulfonyl fluoride. Five milliliters of homogenization buffer was used per gram of brain tissue and homogenized using six passes of a motorized Wheaton Teflon pestle tissue grinder. Homogenates were centrifuged (500×*g*) for 10 min to remove particulate matter and snap-frozen at −80°C. Table [2](#Tab2){ref-type="table"} provides the details of these cases. Table 2List of cases used for 2D PAGE and Western blotsCase numberSexAge (years)DiagnosisRegionPMI (h)Braak stageNIA ReaganAD7F69ADMC225/6HighAD8F79ADMC185/6HighAD9F76ADMC235/6HighC6F86HVDMC6LowC7F73ABDMC24LowC8M63SSMC38Low*PMI* postmortem index, *AD* Alzheimer's disease, *F* female, *M* male, *MC* midfrontal cortex, *C* control, *HVD* hypertensive vascular disease, *ABD* anoxic brain damage, *SS* septic shock

Sample preparation {#Sec8}
------------------

Aliquots (100 μl) of Alzheimer's and control brain homogenates underwent a 2D clean up as per the Amersham Biosciences protocol. The samples were then resolubilized in 300 μl of TUC pH 4--7 buffer containing 7 M urea, 2 M thiourea, 4% CHAPS, 0.5% dithiothreitol, 0.5% IPG buffer pH 4--7. Samples were then assayed for total protein content. Prior to rehydration of the immobilized pH gradient strips, trace amounts of bromophenol blue was added to samples. Table [2](#Tab2){ref-type="table"} provides a list of cases used in the 2D electrophoresis.

2D polyacrylamide gel electrophoresis (PAGE) {#Sec9}
--------------------------------------------

### Isoelectric focusing {#Sec10}

Isoelectric focusing was performed on 13 cm immobilized pH gradient strips (pH 4--7NL, Amersham Pharmacia) using an IPGphor (Amersham Pharmacia) isoelectric focusing unit. Samples were applied in gel rehydration (50 V, overnight) using 7 M urea, 2 M thiourea, 4% CHAPS, 0.5% dithiothreitol, 0.5% pharmalyte pH 4--7 with a trace of bromophenol blue as the re-swell buffer with a total loading volume of 280 μl including sample. Stained gels received a 400 μg protein load and Western blotting gels received a 200 μg load. IEF was performed for ∼60 kV h (500 V 30 min, 1,000 V 30 min, 1,000--8,000 V 30 min, 8,000 V 5--7 h, 1,000 V hold to end).

### SDS PAGE {#Sec11}

SDS PAGE was performed using 12.5% acrylamide gels. Immobilized pH gradient strips were incubated in SDS equilibration buffer containing 1% w/v dithiothreitol for 15 min followed by SDS equilibration buffer containing 4% w/v iodoacetamide for 15 min. Strips were then placed above the second dimension gels and overlaid with 1% low melting point agarose in Tris glycine gel running buffer. Electrophoresis was performed at 350 V for 2.5--3 h at 10°C. Protein gels were visualized using SYPRO ruby fluorescent stain (incubated for 2 h) and scanned using a Typhoon 9400 Variable Mode Imager (Amersham Biosciences).

Western blotting {#Sec12}
----------------

Separated proteins were transferred onto low fluorescence PVDF membrane by semi-dry electroblotting at 0.8 mA/cm^2^ for 2 h. After blocking, the membranes were incubated in affinity-purified rabbit antiperoxiredoxin 6 antibodies (1/2,000) overnight at 4°C followed by goat antirabbit alkaline phosphatase antibodies (1/10,000) (Sigma) for 1 h and visualized using ECF substrate and a Typhoon 9400 Variable Mode Imager.

Immunohistochemistry {#Sec13}
--------------------

### Localization of peroxiredoxin 6 {#Sec14}

Immunohistochemical staining of AD and control tissue was carried out as previously described \[[@CR30]\]. The cellular distribution of peroxiredoxin 6 was compared with the staining obtained with antibodies to specific cellular markers. Antibodies to GFAP (astrocytes), HLA (MHC2) (microglia), MBP (oligodendrocytes) and HuC/HuD (neurons) were used to map the distribution of peroxiredoxin 6.

### Colocalization of peroxiredoxin 6, Aβ and Tau {#Sec15}

Brain sections were incubated with rabbit antiperoxiredoxin 6, mouse anti Aβ peptide and goat anti tau antibodies overnight and detected with secondary antibodies conjugated to fluorescent fluorophores Cy5, Alexa 488 and Cy3, respectively. Sections were examined using a Bio-Rad Confocal laser scanning microscope and Bio-Rad software package, as previously described \[[@CR30]\].

### Cell counting {#Sec16}

Cell counting was carried out blind on masked sections, and peroxiredoxin 6 positive astrocytes were counted at 20× magnification with a graticule eye piece (0.0625 mm^2^) using an Olympus HO-2 microscope on brain tissue from six AD and six control cases. In each case, five regions were randomly selected to give a uniform representation of the white and gray matter in the cingulate, hippocampus, amygdala and midfrontal cortex. The number of positive cells from each of the five areas was averaged and divided by the area of the graticule eyepiece and expressed as cells/mm^2^. The data was then analyzed using a one-way ANOVA that examined the interactions listed in Table [3](#Tab3){ref-type="table"}. The significance was determined at 0.01 level of probability. Table 3Interactions examined in cell counting dataInteractions examined*F* valueCritical *F* (*P* = 0.01)Significance (\>0.01)Are there differences in AD (C, A, H, MC) gray matter cell counts?1.004.94NSAre there differences in AD (C, A, H, MC) white matter cell counts?1.234.94NSAre there differences in control (C, A, H, MC) gray matter cell counts?0.624.94NSAre there differences in control (C, A, H, MC) white matter cell counts?0.254.94NSAre there differences between gray and white matter cell counts in AD tissue?89.37.21SAre there differences between gray and white matter cell counts in control tissue?14.57.21SAre there differences in gray matter cell counts between control and AD tissue?2997.21SAre there differences in white matter cell counts between control and AD tissue?28.07.21S*AD* Alzheimer's disease, *NS* not significant, *S* significant, *C* cingulate, *A* amygdala, *H* hippocampus, *MC* midfrontal cortex

Results {#Sec17}
=======

Molecular forms of peroxiredoxin 6 in human brain {#Sec18}
-------------------------------------------------

We have previously shown that this antibody is specific for a 26 kDa monomer in rat lung and human brain, and the N-terminal sequence is identical to peroxiredoxin 6 \[[@CR30], [@CR31]\]. Two-dimensional PAGE and Western blotting of AD and control brain homogenates indicated that this protein exists as three major and five minor forms as shown in Fig. [1](#Fig1){ref-type="fig"}a--d. Although the loadings were consistent, the five minor forms could not be detected on all gels. For comparison, the spots were labeled 1--8 (Fig. [2](#Fig2){ref-type="fig"}). Fig. 1**a**, **b** A two-dimensional PAGE gel and blot of AD brain tissue (Case AD7) and a corresponding control brain gel and blot panels (**c**, **d**) (Case C7). *pI 4--6* is indicated between the gel and blots and the molecular weight of the standards (Std) in kilo Daltons is shown on the *Y*-axis. The gels were stained with SYPRO ruby fluorescent stain. The *box* indicates the location of the molecular forms of peroxiredoxin 6. Some *spots* are shown on the blots to indicate the range of peroxiredoxin 6 pIsFig. 2A composite figure at higher magnification showing the range of molecular forms in three cases of AD tissue (**a** AD7, AD8 and AD9) and three cases of control tissue (**b** C7, C6 and C8). The range of molecular forms *1--8* is shown, but not all forms are present in all cases. Although there are slight variations between blots, the respective pIs are as follows: 1 (5.3), 2 (5.4), 3 (5.6), 4 (5.75), 5 (5.85), 6 (5.9), 7 (5.95), 8 (6.1)

The respective pIs of the eight forms are 5.3, 5.4, 5.6, 5.75, 5.85, 5.9, 5.95 and 6.1. The three major forms were 3, 6 and 7 and the average pIs of these were 5.59, 5.88 and 5.96 for AD tissue and 5.59, 5.80 and 5.86 for control tissue. These major forms were consistent in all homogenates. The intensity of the three major forms was analyzed using the Typhoon imager and the intensity of spots 6 and 7 was reversed in the AD and control homogenates (Fig. [2](#Fig2){ref-type="fig"}). Minor forms 1 and 2 were present in AD homogenates but absent in the control tissue, while minor form 8 was present in control tissue but absent in AD tissue (Fig. [2](#Fig2){ref-type="fig"}).

Cellular distribution of peroxiredoxin 6 in control and AD brain tissue {#Sec19}
-----------------------------------------------------------------------

Using immunohistochemical markers for specific human brain cell types, we have shown that peroxiredoxin 6 is abundant in reactive astrocytes (Fig. [3](#Fig3){ref-type="fig"}a--c) in AD tissue and present in very low levels in neurons (Fig. [3](#Fig3){ref-type="fig"}j--l). We were not able to detect peroxiredoxin 6 in either microglia (Fig. [3](#Fig3){ref-type="fig"}d--f) or oligodendrocytes (Fig. [3](#Fig3){ref-type="fig"}g--i). Fig. 3Confocal localization of peroxiredoxin 6 (P6) with GFAP (astrocyte marker) (**a** P6, Cy2-*green*; **b** GFAP, Cy3-*red*; **c** merged image; *bar* 25 μM), MHC2 (microglia marker) (**d** P6, Cy2-*green*; **e** MHC2, Cy3-*red*; **f** merged image; *bar* 25 μM), MBP (oligodendrocyte marker) (**g** P6, Cy2-*green*; **h** MBP, Cy3-*red*; **i** merged image; *bar* 10 μM), Hu (neuronal marker) (**j** P6, Cy2-*green*; **k** Hu, Cy3-*red*; **l** merged image; *bar* 25 μM). Cell localization was performed using AD tissue

There was a marked contrast between the staining of control and reactive astrocytes in AD. Reactive astrocytes in AD were hypertrophied with abundant staining of peroxiredoxin 6, while in control astrocytes the staining was confined to a "halo" around the nucleus (Fig. [4](#Fig4){ref-type="fig"}). The increased staining of peroxiredoxin 6 was seen in all regions examined and in both gray and white matter, but the staining was not evenly distributed and some regions on the same section were heavily labeled but adjacent regions showed little staining (Fig. [5](#Fig5){ref-type="fig"}). Fig. 4Oil immersion image (×1,000) of typical astrocyte seen in AD cortex (**a**) and in control cortex (**b**)Fig. 5Light immunohistochemistry (DAB substrate) of peroxiredoxin 6 staining of astrocytes in AD *gray* matter (**a**), AD *white* matter (**b**), control tissue *gray* matter (**c**) and control tissue *white* matter (**d**). All images at ×200 magnification

Cell counting {#Sec20}
-------------

In AD and control tissue, peroxiredoxin 6 was colocalized with GFAP, indicating that the upregulation is occurring in astrocytes, which is similar to what was found in PD and dementia with Lewy bodies \[[@CR30]\]. Cell counting was conducted on midfrontal cortex, cingulate, amygdala and hippocampus brain regions and in gray and white matter to determine if specific areas or matter type were specifically affected. These are summarized in Fig. [6](#Fig6){ref-type="fig"}. A one-way ANOVA was performed comparing the cell counts between AD and control tissue in different regions by tissue and matter type. The results of the interactions examined are shown in Table [3](#Tab3){ref-type="table"}. Fig. 6A *bar chart* showing the range of cell counts in different brain regions in gray and white matter in control tissue and in AD tissue. *WM* white matter, *GM* gray matter, *Cing* cingulate, *Amy* amygdala, *MFC* midfrontal cortex, *Hip* hippocampus. Counts are shown as mean ± SE, *N* = 6 in all cases

Colocalization of peroxiredoxin 6 and AD pathology {#Sec21}
--------------------------------------------------

The major defining pathology in AD is the presence of extracellular plaques and intracellular hyperphosphorylated tau in the form of tangles. Plaques are present in brain tissue at different stages of development, ranging from diffuse plaques to fibrillar and neuritic plaques. It is generally considered that diffuse plaques do not contain tau, but neuritic plaques contain both Aβ and tau. Colocalization of peroxiredoxin 6 and the Aβ peptide, a major component of plaques, and tau was carried out to determine if peroxiredoxin 6 positive astrocytes were associated with AD pathology.

### Tau pathology {#Sec22}

Tau deposits in the form of neurofibrillary tangles were observed in many neurons and neurites, and were often surrounded by peroxiredoxin 6 astrocytes, which made multiple contacts (Fig. [7](#Fig7){ref-type="fig"}a--c). Although astrocytes made many contacts with neurons, most neurons had very low levels of peroxiredoxin 6 and it did not appear to be upregulated or to be colocalized with tau in AD. Fig. 7**a--c** Confocal localization of tau within neurons (**a** Cy2-*green*) and peroxiredoxin 6 positive astrocytes (**b** Cy3-*red*) and (**c**) the merged image in AD brain tissue (*bar* = 10 μM). **d--f** Confocal localization of Aβ peptide (**d** Alexa 488, *green*) and peroxiredoxin 6 positive astrocytes (**e** Cy3-red) and (**f**) the merged image in a diffuse plaque in AD brain tissue (*bar* = 50 μM). **g--j** Confocal localization of Aβ peptide (Alexa 488, *green*) and peroxiredoxin 6 positive astrocytes (Cy5-*light blue*) in four different plaques in AD brain tissue (*bar* = 50 μM). **k** Immunohistochemical staining (DAB substrate) showing peroxiredoxin 6 staining of astrocytes and astrocyte foot processes in the walls of blood vessels in the midfrontal cortex in Alzheimer's disease (×400). *Arrows* indicate peroxiredoxin 6 positive astrocytic processes

### Plaques {#Sec23}

Diffuse plaques contained strongly stained aggregations of Aβ peptide. Peroxiredoxin 6 staining was confined to astrocytes and their projections that were in close proximity to plaques (Fig. [7](#Fig7){ref-type="fig"}d--h). Some astrocytes were observed within plaques, but generally the astrocyte cell bodies were on the periphery with their processes projecting into the plaques. Some plaques contained the beginnings of a dense core of amyloid and took on a "wagon wheel" appearance (Fig. [7](#Fig7){ref-type="fig"}i, j). Diffuse plaques and those with Aβ beginning to aggregate appeared to elicit a stronger peroxiredoxin 6 astrocytic response than those with a dense core of Aβ.

Peroxiredoxin 6 staining of blood vessels {#Sec24}
-----------------------------------------

In many regions of the AD brain, there appeared to be strong peroxiredoxin 6 staining in the walls of many blood vessels, which could be seen to have multiple contacts with strongly staining activated astrocytes (Fig. [7](#Fig7){ref-type="fig"}k).

Discussion {#Sec25}
==========

Peroxiredoxin 6, also known as 1-Cys peroxiredoxin or non-selenium glutathione peroxidase, is a human brain antioxidant enzyme that is abundant in activated astrocytes and present in low levels in neurons. On exposure to hydrogen peroxide, the N-terminal peroxiredoxin 6 corresponding to Cys 47 is readily oxidized, but as yet its redox partner has not been identified. Glutathione, lipoic acid and cyclophilin have all been implicated \[[@CR13], [@CR23], [@CR29]\]. In addition to its peroxidase activity, peroxiredoxin 6 also has phospholipase A2 activity that might be significant in the brain, which has a high lipid content \[[@CR9]\]. Peroxiredoxin 6 staining of astrocytes is markedly elevated in many brain regions in PD and dementia with Lewy bodies \[[@CR30]\]. We now show that it is upregulated in the astrocytes in AD and describe for the first time the range of molecular forms of peroxiredoxin 6 in human brain in both control and AD tissue.

Three major variants and five minor forms were identified with pIs ranging from 5.3 to 6.1. There were three major differences in the peroxiredoxin 6 variants between control and AD tissue. The AD tissue had the two more acidic forms 1 and 2 that were not present in control tissue; the intensity of the major forms 6 and 7 were reversed between AD and control tissue and minor form 8 was absent in AD tissue. We can only speculate on the significance of these findings at this stage, but different forms may have different affinities for different substrates that might be more abundant under various pathological conditions or the more acidic forms are the result of oxidation \[[@CR11]\]. At this stage, we cannot determine whether these differences are true isoforms or post-translational modifications of the same protein, but would suspect the latter. These findings are in agreement with two previous proteomic studies in an AD mouse model and in human brain AD tissue, which reported elevated levels of peroxiredoxin 6 \[[@CR33], [@CR34]\]. A more recent study using PC12-resistant and PC12 cells treated with Aβ also reported increased levels of peroxiredoxin 6 \[[@CR11]\]. Aβ-treated cells contained an extra acidic form, which was suggested to be the result of oxidation of the catalytic cysteine to a sulfenic, sulfinic or sulfonic derivative. We found two minor acidic forms in AD tissue, which is also consistent with this report.

Tissue selection is also a variable that needs to be considered. While the AD tissue had all the hallmarks of AD pathology and was easy to define, age-matched control tissues are somewhat more variable. All the control tissue was from people without clinically defined AD, but most brains in this age group usually contain some neurodegenerative pathology. The age span of the two groups was similar, 59--84 years for the AD group and 61--86 years for the control group, but the mean age for the control group was 7 years older. We feel confident that, although some control tissue may have had some elements of subclinical AD pathology, the reduced level of astrocyte activation and the clear differences in the cell counting would indicate that all the control tissues were not experiencing high levels of oxidative stress as compared to the AD tissue.

Previously, we had shown that peroxiredoxin 6 was abundant in astrocytes in PD and dementia with Lewy body tissue \[[@CR30]\]. We have now used cellular markers to other brain cell types to show that in addition to astrocytes there is a low level in the cytoplasm of most neurons. Unlike astrocytes, neurons do not appear to have increased peroxiredoxin 6 staining in AD tissue. We could not detect any peroxiredoxin 6 staining in microglia or oligodendrocytes.

Cell counting of peroxiredoxin 6 positive astrocytes indicated that there was a marked increase in both the gray and white matter in AD tissue compared with control tissue. Gray matter had more peroxiredoxin 6 positive astrocytes than white matter in both AD and control tissue, and this difference was more pronounced in AD tissue with *F* values of 89.0 and 14.5, respectively. Considering that the major pathology (plaques and tangles) is located in the gray matter, it would be expected that oxidative stress is more pronounced in this area. Cell counting indicated that the peroxiredoxin 6 positive astrocyte numbers were elevated in all regions examined, suggesting that the insult activating astrocytes is wide spread and not confined to any specific region in either the gray or white matter. Indeed, extracellular plaques were observed in all regions examined in AD tissue. Although all regions examined showed astrocyte activation, this was not uniformly distributed through all areas, with some areas showing extensive astrocyte activation while adjacent areas were similar to controls.

There are two defining pathologies in AD. These are the presence of extracellular plaques comprising abundant deposits of Aβ peptides, which later aggregate to form amyloid \[[@CR25]\] and intracellular hyperphosphorylated tau aggregations in the form of paired helical filaments, which are termed tangles \[[@CR14], [@CR22]\]. The two well-described forms of plaques have been termed diffuse plaques and neuritic or senile plaques \[[@CR12], [@CR18]\], although other intermediate forms such as fibrillar plaques have been described \[[@CR12]\]. Diffuse plaques are spherical structures of less dense Aβ deposits and are considered an early stage of plaque formation. In diffuse plaques, aggregations of Aβ exists as nonamyloid deposits, but as the plaque progresses, the Aβ and other protein aggregations change from the normal conformation into a β-sheet structure, termed amyloid, and take up specific dyes like Congo red and thioflavin \[[@CR4]\]. These plaques do not generally contain tau; however, in many confocal images, diffuse plaques contain focal points of tau, which are probably enlarged neurites. Neuritic or senile plaques contain a dense core of amyloid enriched with Aβ peptide with a corona of less dense amyloid. The diffuse plaques appeared to elicit a stronger astrocytic response based on the level of peroxiredoxin 6 staining than the neuritic plaques. Our images suggest that once the Aβ forms amyloid and condenses, it is less stimulating toward astrocytes and perhaps the formation of amyloid is a protective mechanism to inactivate the toxicity of soluble Aβ. These observations are consistent with the findings of Kawaguchi-Niida et al., who reported that the highly reactive carbonyl crotonaldehyde generated during lipid peroxidation is localized to reactive astrocytes, microglia and diffuse plaques but undetectable in amyloid cores \[[@CR19]\].

Although the activation of astrocytes and upregulation of peroxiredoxin 6 would be considered a protective response, in cell culture, soluble Aβ has been shown to stimulate nitric oxide synthetase and the production of nitric oxide, which is very damaging to neurons \[[@CR17]\]. This response is further upregulated by other inflammatory cytokines such as interleukin 1β and tumour necrosis factor-α, which are reported to be released from astrocytes \[[@CR1]\]. At this stage, we are not sure of the net benefit to neural tissue of activated astrocytes with elevated levels of peroxiredoxin 6, concomitant with the increased production of nitric oxide.

Neurofibrillary tangles comprising hyperphosphorylated tau were observed in many regions in AD tissue. Two antibodies were used to localize tau, a monoclonal antibody (Novacastra) and one specific for paired helical filaments (Santa Cruz) and both produced a similar staining pattern. Neurons containing tau were not surrounded by activated astrocytes as were the diffuse plaques and to a lesser extent the neuritic plaques, suggesting that these cells are not secreting toxic or activating products that are stimulating to astrocytes. In PD, Lewy bodies contained a dense core of peroxiredoxin 6 staining suggesting that it was trying to detoxify oxidative stress produced by Lewy bodies, but we did not observe any interaction between tau and peroxiredoxin 6 in AD tissue. Although there is considerable evidence to implicate oxidative stress in the hyperphosphorylation of tau, this does not appear to upregulate peroxiredoxin 6 in tau positive neurons.

In some regions, the walls of blood vessels exhibited strong peroxiredoxin 6 staining, which also elicited a strong astrocytic response in surrounding astrocytes. These activated astrocytes had many processes in contact with the endothelial cells. Although vascular amyloid deposits were seen in some sections and is a key feature of AD \[[@CR28]\], the upregulation of peroxiredoxin 6 appeared to occur in regions without distinct Aβ staining. Aβ has been shown to induce vascular vasoconstriction in rat skin, which can be reversed by superoxide dismutase and catalase, indicating that Aβ is capable of generating ROS within blood vessels \[[@CR21]\]. The blood brain barrier consists of the capillary endothelial cells, and the foot processes of the astrocytes and the fused basal lamina of both cells. The peroxiredoxin 6 staining within the capillaries appears to be in the foot processes of the astrocytes. Whether this increased staining is due to ROS generated from within neural tissue or reflects a more systemic pathology derived from the circulation is unclear.

In conclusion, we have shown for the first time the range of peroxiredoxin 6 variants, which are either isoforms or post-translational modifications in human brain tissue. We have also shown that peroxiredoxin 6 is primarily an astrocytic enzyme with very low levels in neurons and is not detectable in microglia or oligodendrocytes. This enzyme is markedly elevated in astrocytes in both white and gray matter in AD. Strongly staining peroxiredoxin 6 astrocytes appear to be involved in the detoxification of diffuse plaques and to a lesser extent in neuritic plaques, but is not associated with tau aggregations within neurons. From this work and previous work on PD and dementia with Lewy bodies, we suggest that peroxiredoxin 6 is a major antioxidant enzyme in human neural tissue.
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